Houston researchers are hard at work in the lab to progress medical advancements at the bedside. Getty Images

Every day, important research is being completed under the roofs of Houston medical institutions. From immunotherapy to complex studies on how a memory is made, Houston researchers are discovering and analyzing important aspects of the future of medicine.

Here are three research projects currently being conducted around town.

University of Houston's potential solution to sickle cell disease

Vassiliy Lubchenko is a University of Houston associate professor of chemistry. Courtesy of UH

For the most part, sickle cells have been a mystery to scientists, but one University of Houston professor has recently reported a new finding on how sickle cells are formed — enlightening the medical community with hopes that better understanding the disease may lead to prevention.

Vassiliy Lubchenko, UH associate professor of chemistry, shared his new finding in Nature Communications. He reports that "droplets of liquid, enriched in hemoglobin, form clusters inside some red blood cells when two hemoglobin molecules form a bond — but only briefly, for one thousandth of a second or so," reads a release from UH.

In sickle cell disease, or anemia, red blood cells are crescent shaped and don't flow as easily through narrow blood vessels. The misshapen cells are caused by abnormal hemoglobin molecules that line up into stiff filaments inside red blood cells. Those filaments grow when the protein forms tiny droplets called mesoscopic.

"Though relatively small in number, the mesoscopic clusters pack a punch," says Lubchenko in the release. "They serve as essential nucleation, or growth, centers for things like sickle cell anemia fibers or protein crystals. The sickle cell fibers are the cause of a debilitating and painful disease, while making protein crystals remains to this day the most important tool for structural biologists."

Lubchenko conclusion is that the key to prevent sickle cell disease is to is to stop the formation of the initial clusters so fibers aren't able to grow out of them.

Baylor College of Medicine's immunotherapy research in breast cancer

science-Digital Composite Image Of Male Scientist Experimenting In Laboratory

Baylor College of Medicine researchers are looking into the complexities of immune cells in breast cancer. Getty Images

Baylor College of Medicine researchers are leading an initiative to figure out the potential effect of immunotherapy on different types of breast cancers. Their report is featured in Nature Cell Biology.

The scientists zoned in on two types of immune cells — neutrophils and macrophages — and they found frequency differed in a way that indicated potential roles in immunotherapy.

"Focusing on neutrophils and macrophages, we investigated whether different tumors had the same immune cell composition and whether seemingly similar immune components played the same role in tumor growth. Importantly, we wanted to find out whether differences in immune cell composition contributed to the tumors' responses to immunotherapy," says Dr. Xiang 'Shawn' Zhang, professor at the Lester and Sue Smith Breast Center and member of the Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine, in a news release.

Further exploring the discrepancies between the immune cells and the role they play in tumor growth will help better understand immunotherapy's potential in certain types of breast cancer.

"These findings are just the beginning. They highlight the need to investigate these two cellular types deeper. Under the name 'macrophages' there are many different cellular subtypes and the same stands for neutrophils," Zhang says. "We need to identify at single cell level which subtypes favor and which ones disrupt tumor growth taking also into consideration tumor heterogeneity as both are relevant to therapy."

Rice University, UTHeath, and UH's memory-making study

Researchers from all corners of Houston are diving into how memories are made. Courtesy of Rice University

When you make a memory, your brain cells structurally change. Through a multi-institutional study with researchers from UH, Rice University, and the University of Texas Health Science Center at Houston, we now know more about the way memories are made.

When forming memories, three moving parts work together in the human brain — a binding protein, a structural protein and calcium — to allow for electrical signals to enter neural cells and change the molecular structures in cognition. The scientists compared notes on how on that binding protein works.

The team's study was published in the Proceedings of the National Academy of Sciences. Peter Wolynes, a theoretical physicist at Rice, UH physicist Margaret Cheung, and UTHealth neurobiologist Neal Waxham worked together to understand the complex process memories experience in the process of being made.

"This is one of the most interesting problems in neuroscience: How do short-term chemical changes lead to something long term, like memory?" Waxham says in a release from Rice. "I think one of the most interesting contributions we make is to capture how the system takes changes that happen in milliseconds to seconds and builds something that can outlive the initial signal."

Three UH researchers are revolutionizing the way we think the brain works. Andriy Onufriyenko/Getty Images

3 ways University of Houston researchers are innovating brain treatments and technologies

Brain teasers

While a lot of scientists and researchers have long been scratching their heads over complicated brain functionality challenges, these three University of Houston researchers have made crucial discoveries in their research.

From dissecting the immediate moment a memory is made or incorporating technology to solve mobility problems or concussion research, here are the three brain innovations and findings these UH professors have developed.

Brains on the move

Professor of biomedical engineering Joe Francis is reporting work that represents a significant step forward for prosthetics that perform more naturally. Photo courtesy of UH Research

Brain prosthetics have come a long way in the past few years, but a UH professor and his team have discovered a key feature of a brain-computer interface that allows for an advancement in the technology.

Joe Francis,a UH professor of biomedical engineering, reported in eNeuro that the BCI device is able to learn on its own when its user is expecting a reward through translating interactions "between single-neuron activities and the information flowing to these neurons, called the local field potential," according to a UH news release. This is all happening without the machine being specifically programmed for this capability.

"This will help prosthetics work the way the user wants them to," says Francis in the release. "The BCI quickly interprets what you're going to do and what you expect as far as whether the outcome will be good or bad."

Using implanted electrodes, Francis tracked the effects of reward on the brain's motor cortex activity.

"We assume intention is in there, and we decode that information by an algorithm and have it control either a computer cursor, for example, or a robotic arm," says Francis in the release.

A BCI device would be used for patients with various brain conditions that, as a result of their circumstances, don't have full motor functionality.

"This is important because we are going to have to extract this information and brain activity out of people who cannot actually move, so this is our way of showing we can still get the information even if there is no movement," says Francis.

Demystifying the memory making moments

Margaret Cheung, a UH professor, is looking into what happens when a memory is formed in the brain. Photo courtesy of UH Research

What happens when a brain forms a new memory? Margaret Cheung, a UH professor in the school of physics, computer science, and chemistry, is trying to find out.

Cheung is analyzing the exact moment a neuron forms a memory in our brains and says this research will open doors to enhancing memory making in the future.

"The 2000 Nobel laureate Eric Kandel said that human consciousness will eventually be explained in terms of molecular signaling pathways. I want to see how far we can go to understand the signals," says Cheung in a release.

Cheung is looking at calcium in particular, since this element impacts most of cellular life.

"How the information is transmitted from the calcium to the calmodulin and how CaM uses that information to activate decisions is what we are exploring," says Cheung in the release. "This interaction explains the mechanism of human cognition."

Her work is being funded by a $1.1 million grant from the National Institute of General Medical Science from the National Institutes of Health, and she's venturing into uncharted territories with her calcium signaling studies. Previous research hasn't been precise or conclusive enough for real-world application.

"In this work we seek to understand the dynamics between calcium signaling and the resulting encoded CaM states using a multiphysics approach," says Cheung. "Our expected outcome will advance modeling of the space-time distribution of general secondary messengers and increase the predictive power of biophysical simulations."

New tech for brain damage treatment

Badri Roysam, chair of the University of Houston Department of Electrical and Computer Engineering, is leading the project that uncovering new details surrounding concussions. Photo courtesy of UH Research

Concussions and brain damage have both had their fair shares of question marks, but this UH faculty member is tapping into new technologies to lift the curtain a little.

Badri Roysam, the chair of the University of Houston Department of Electrical and Computer Engineering, is heading up a multimillion-dollar project that includes "super microscopes" and the UH supercomputer at the Hewlett Packard Enterprise Data Science Institute. Roysam calls the $3.19 million project a marriage between these two devices.

"By allowing us to see the effects of the injury, treatments and the body's own healing processes at once, the combination offers unprecedented potential to accelerate investigation and development of next-generation treatments for brain pathologies," says Roysam in a release.

The project, which is funded by the National Institute of Neurological Disorders and Stroke (NINDS), is lead by Roysam and co-principal investigator John Redell, assistant professor at UTHealth McGovern Medical School. The team also includes NINDS scientist Dragan Maric and UH professors Hien Van Nguyen and Saurabh Prasad.

Concussions, which affect millions of people, have long been mysterious to scientists due to technological limitations that hinder treatment options and opportunities.

"We can now go in with eyes wide open whereas before we had only a very incomplete view with insufficient detail," says Roysam in the release. "The combinations of proteins we can now see are very informative. For each cell, they tell us what kind of brain cell it is, and what is going on with that cell."

The technology and research can be extended to other brain conditions, such as strokes, brain cancer, and more.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston hospitals win $50M grant for ibogaine addiction treatment research

ibogaine funding

The Texas Health and Human Services Commission has awarded $50 million to UTHealth Houston in collaboration with The University of Texas Medical Branch at Galveston (UTMB Health) to co-lead a multicenter research trial to evaluate the effect of ibogaine, a powerful psychoactive compound, on patients suffering from addiction, traumatic brain injury and other behavioral health conditions.

The funding will establish a two-year initiative—known as Ibogaine Medicine for PTSD, Addiction, and Cognitive Trauma (IMPACT)—and a consortium of Texas health institutions focused on clinical trials and working toward potential FDA-approved treatments.

The consoritum will also include Texas Tech University, Texas Tech University Health Sciences Center El Paso, The University of Texas at Austin, The University of Texas Health Science Center at San Antonio, The University of Texas at Tyler, The University of Texas Rio Grande Valley, Texas A&M University, The University of North Texas Health Science Center, Baylor College of Medicine and JPS Health Network in Dallas.

Ibogaine is a plant-based, psychoactive substance derived from the iboga shrub. Research suggests that the substance could be used for potential treatment for patients with traumatic brain injuries, which is a leading cause of post-traumatic stress disorders. Ibogaine has also shown potential as a treatment for addiction and other neurological conditions.

UTHealth and partners will focus on ways that ibogaine can treat addiction and associated conditions. Meanwhile, UT Austin and Baylor College of Medicine will concentrate on using it to treat traumatic brain injury, especially in veterans, according to a news release from the institutions.

The consortium will also support drug developers and teaching hospitals to conduct FDA-approved clinical trials. The Texas Health and Human Services Commission will oversee the grant program.

“This landmark clinical trial reflects our unwavering commitment to advancing research that improves lives and delivers the highest standards of care,” Dr. Melina Kibbe, UTHealth Houston president and the Alkek-Williams Distinguished Chair, said in the news release. “By joining forces with outstanding partners across our state, we are building on Texas’ tradition of innovation to ensure patients struggling with addiction and behavioral health conditions have access to the best possible outcomes. Together, we are shaping discoveries that will serve Texans and set a model for the nation.”

The consortium was authorized by the passage of Senate Bill 2308. The bill provides $50 million in state-matching funds for an ibogaine clinical trial managed by a public university in partnership with a drug company and a hospital.

“This is the first major step towards the legislature’s goal of obtaining FDA approval through clinical trials of ibogaine — a potential breakthrough medication that has brought thousands of America’s war-fighters back from the darkest parts of depression, anxiety, PTSD, and chronic addiction,” Texas Rep. Cody Harris added in the release. “I am excited to walk alongside UTHealth Houston and UTMB as these stellar institutions lead the nation in a first-of-its-kind clinical trial in the U.S.”

Recently, the University of Houston also received a $2.6 million gift from the estate of Dr. William A. Gibson to support and expand its opioid addiction research, which includes the development of a fentanyl vaccine that could block the drug's ability to enter the brain. Read more here.

Tesla no longer world's biggest EV maker as sales fall for second year

Tesla Talk

Tesla lost its crown as the world’s bestselling electric vehicle maker as a customer revolt over Elon Musk’s right-wing politics, expiring U.S. tax breaks for buyers and stiff overseas competition pushed sales down for a second year in a row.

Tesla said that it delivered 1.64 million vehicles in 2025, down 9% from a year earlier.

Chinese rival BYD, which sold 2.26 million vehicles last year, is now the biggest EV maker.

It's a stunning reversal for a car company whose rise once seemed unstoppable as it overtook traditional automakers with far more resources and helped make Musk the world's richest man. The sales drop came despite President Donald Trump's marketing effort early last year when he called a press conference to praise Musk as a “patriot” in front of Teslas lined up on the White House driveway, then announced he would be buying one, bucking presidential precedent to not endorse private company products.

For the fourth quarter, Tesla sales totaled 418,227, falling short of even the much reduced 440,000 target that analysts recently polled by FactSet had expected. Sales were hit hard by the expiration of a $7,500 tax credit for electric vehicle purchases that was phased out by the Trump administration at the end of September.

Tesla stock fell 2.6% to $438.07 on Friday.

Even with multiple issues buffeting the company, investors are betting that Tesla CEO Musk can deliver on his ambitions to make Tesla a leader in robotaxi services and get consumers to embrace humanoid robots that can perform basic tasks in homes and offices. Reflecting that optimism, the stock finished 2025 with a gain of approximately 11%.

The latest quarter was the first with sales of stripped-down versions of the Model Y and Model 3 that Musk unveiled in early October as part of an effort to revive sales. The new Model Y costs just under $40,000 while customers can buy the cheaper Model 3 for under $37,000. Those versions are expected to help Tesla compete with Chinese models in Europe and Asia.

For fourth-quarter earnings coming out in late January, analysts are expecting the company to post a 3% drop in sales and a nearly 40% drop in earnings per share, according to FactSet. Analysts expect the downward trend in sales and profits to eventually reverse itself as 2026 rolls along.

Musk said earlier last year that a “major rebound” in sales was underway, but investors were unruffled when that didn't pan out, choosing instead to focus on Musk's pivot to different parts of business. He has has been saying the future of the company lies with its driverless robotaxis service, its energy storage business and building robots for the home and factory — and much less with car sales.

Tesla started rolling out its robotaxi service in Austin in June, first with safety monitors in the cars to take over in case of trouble, then testing without them. The company hopes to roll out the service in several cities this year.

To do that successfully, it needs to take on rival Waymo, which has been operating autonomous taxis for years and has far more customers. It also will also have to contend with regulatory challenges. The company is under several federal safety investigations and other probes. In California, Tesla is at risk of temporarily losing its license to sell cars in the state after a judge there ruled it had misled customers about their safety.

“Regulatory is going to be a big issue,” said Wedbush Securities analyst Dan Ives, a well-known bull on the stock. “We're dealing with people's lives.”

Still, Ives said he expects Tesla's autonomous offerings will soon overcome any setbacks.

Musk has said he hopes software updates to his cars will enable hundreds of thousands of Tesla vehicles to operate autonomously with zero human intervention by the end of this year. The company is also planning to begin production of its AI-powered Cybercab with no steering wheel or pedals in 2026.

To keep Musk focused on the company, Tesla’s directors awarded Musk a potentially enormous new pay package that shareholders backed at the annual meeting in November.

Musk scored another huge windfall two weeks ago when the Delaware Supreme Court reversed a decision that deprived him of a $55 billion pay package that Tesla doled out in 2018.

Musk could become the world's first trillionaire later this year when he sells shares of his rocket company SpaceX to the public for the first time in what analysts expect would be a blockbuster initial public offering.

8+ can't-miss Houston business and innovation events in January

where to be

Editor's note: Kick off 2026 by hearing insightful talks and making meaningful connections in Houston's innovation scene. From networking workshops to presentations from major industry leaders, here's what not to miss and how to register. Please note: this article may be updated to include additional event listings.

Jan. 13 – Financing the Future

Hear from James Blake, head of capital markets at Fervo Energy, in this informative talk. Blake will cover the current investment landscape for geothermal power, how geothermal projects are structured and the role of policy incentives and innovative financing models in moving the industry forward. A small reception follows.

This event is Tuesday, Jan. 13, from 5:30-7:30 p.m. at the Ion. Register here.

Jan. 13 – Your Path to the Boardroom

Visit Sesh Coworking to hear from Keith Dorsey, an executive advisor and author of The Boardroom Journey, as he shares insights and lessons from hundreds of corporate board members and presents an actionable roadmap for women at every stage of their careers. Dorsey will speak on what "optimal diversity” means in the boardroom, how purpose-driven leaders sustain resilience under relentless pressure and why inclusive leadership is non-negotiable for growth and innovation.

This event is Tuesday, Jan. 13, from 6-8 p.m. at Sesh Coworking. Register here.

Jan. 14 — A Conversation with Dr. Wayne J. Riley on Leading Through Healthcare Transformation

Rice Business Partners will host Dr. Wayne J. Riley, president of SUNY Downstate Health Sciences University, for a moderated discussion with Dean Peter Rodriguez. Riley will share insights on leading complex healthcare organizations in an era of unprecedented industry challenges and reflect on his time at the Jones Graduate School of Business.

This event is Wednesday, Jan. 14, from 6:30-8:30 p.m. at McNair Hall on Rice University's campus. Register here.

Jan. 14 — VDW: Igniting Connections for Startup Success

Entrepreneurial communications instructor Diana Massaro will lead Lilie's latest Venture Development Workshop, focused on soft skills like clear communication, active listening and compelling introductions. Attendees will gain a personalized networking game plan and communication tools to turn casual encounters into meaningful relationships to support their ventures or careers.

This event is Wednesday, Jan. 14, from 6-7:30 p.m. at the Liu Idea Lab for Innovation and Entrepreneurship on Rice University's campus. Register here.

Jan. 21 — Upstream: Digital Tech Meetup

This month's Upstream: Digital Tech Meetup will explore how AI and real-time monitoring are being applied in safety-critical offshore environments, what’s working today, where the biggest gaps remain going into 2026 and how operators and service companies are approaching adoption. Expect to hear from leaders at NOV, Incom Solutions, Timbergrove and others.

This event is Wednesday, Jan. 21, from 8:30-10:30 a.m. at the Ion. Find more information here.

Jan. 22 — HEAD AND HEART: Leading Technology with Humanity While Everything Changes

Hear from Chris Hyams, former CEO of Indeed, at the latest installment of Rice's Master of Engineering Management & Leadership Seminar Series. Hyams will present on the intersection of technology, humanity and change—and how AI is reshaping all three.

This event is Thursday, Jan. 22, at 6 p.m. at Duncan Hall on Rice University's campus. Find more information here.

Jan. 22 – NASA Tech Talk

This month's NASA Tech Talks will feature a special delegation from the UK Science and Technology Network. Expect to hear from a panel of UK space experts, followed by a fireside chat featuring David Alexander, head of the Rice Space Institute, and Meganne Christian, ESA reserve astronaut and senior exploration manager.

This event is Thursday, Jan. 22, from 6-7 p.m. at the Ion. Find more information here.

Jan. 29 – Ignition Hub Startup Career Fair

Lilie will host the Ignition Hub Startup Career Fair this month in partnership with Rice University’s Center for Career Development and Career Development Office. The fair will bring together some of the most innovative, high-growth companies to offer Rice students exciting opportunities. Startups can apply to be considered for the fair. The event is open to Rice University undergraduate, graduate, MBA, and PhD students.

This event is Thursday, Jan. 29, at Grand Hall on Rice University's campus. Find more information here.

Jan. 29 – Health Policy Symposium: Value-Based Care & the Health Care Workforce

The Humana Integrated Health Systems Science Institute at the University of Houston will host its latest Health Policy Symposium this month, focused on the evolving landscape of value-based care and the importance of preparing and strengthening the health care workforce. Hear keynote addresses from leaders at Humana, UH, the American Medical Association and Houston Health Department.

This event is Thursday, Jan. 29, from 11:30 a.m.-1:30 p.m. at the Tilman J. Fertitta Family College of Medicine on Rice University's campus. Find more information here.

Jan. 30 — GHP Annual Meeting

The Greater Houston Partnership's premier event will highlight the region’s progress, honor visionary leadership and set the tone for the year ahead. Hear reflections from outgoing board chair, Gretchen Watkins (former -president of Shell USA); welcome incoming board chair, Armando Perez (EVP of H-E-B Houston); and more

This event is Friday, Jan. 30, from 11:30 a.m.-1:30 p.m. at Hilton Americas. Find more information here.